contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


dagens-aktienyheder-2910-2025-ds-norden-curasight-og-wirtek-as

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

NORDEN is an internationally operating shipping company with 12 global offices, headquartered in Copenhagen, Denmark, and listed on  Nasdaq OMX Copenhagen. The company is present in the dry cargo and product tanker markets with a combination of operator and asset trading activities.

NORDEN’s trading-oriented business model is based on the two business units ‘Assets & Logistics’ and ‘Freight Services & Trading’ – dividing the business into asset trading and operator activities.

The company’s business activities are based on an asset-light trading strategy, only owning a small percentage (~5%) of its total operated vessel fleet consisting of close to 500 vessels. The agility of the business model enables NORDEN to continuously adjust short-term market exposure towards dry cargo and product tanker market developments while capitalizing on asset trading opportunities. In-house data and advanced analytics, risk management, and market research provide a data-driven approach to shipping, making proactive use of volatile markets.

D/S Norden

Curasight is a Danish biotech company focusing on developing and improving the detection and treatment of cancer in a more gentle and efficient way. The company has two pipeline products that both use radionuclide (nuclear medicine) to facilitate better diagnosis and treatment of various cancer types; uTRACE use the so-called uPAR as a biomarker to diagnose the aggressiveness of cancer, and uTREAT use the uPAR as a attachment to treat the cancer.

Based on good phase 2 data that has already been collected or will be in the first half of 2022, Curasight is expected to prepare phase 3 for uTRACE later in 2022 and 2023 for the following four cancer types: prostate, brain, neuroendocrine, and head and neck cancer.

Curasight

WirTek is an IT company. The company is focused on developing software and hardware solutions that affect web, mobile and integrated complete systems. Operations are held on a global level, with the largest presence in the Nordic region and Europe, where customers mainly consist of small and medium-sized business customers. WirTek was founded in 2001 and is headquartered in Aalborg.

Wirtek

Dagens aktienyheder med DS NORDEN, Curasight og Wirtek A/S

Dagens aktienyheder 29/10-2025: <a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/page-posts/published/#" data-entity-urn="urn:li:fsd_company:44013" data-guid="20" data-object-urn="urn:li:organization:44013" data-original-text="DS NORDEN" data-test-ql-mention="true">DS NORDEN</a>, <a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/page-posts/published/#" data-entity-urn="urn:li:fsd_company:9488709" data-guid="21" data-object-urn="urn:li:organization:9488709" data-original-text="Curasight" data-test-ql-mention="true">Curasight</a> og <a class="ql-mention" spellcheck="false" href="https://www.linkedin.com/company/54143576/admin/page-posts/published/#" data-entity-urn="urn:li:fsd_company:45754" data-guid="22" data-object-urn="urn:li:organization:45754" data-original-text="Wirtek A/S" data-test-ql-mention="true">Wirtek A/S</a>
NORDEN opjusterede i g&#xe5;r forventningerne til 2025 op til det planlagte Q3 2025 regnskab der offentligg&#xf8;res i morgen. S&#xe5;ledes venter NORDEN nu et nettoresultat i 2025 p&#xe5; USD 100-140 mio. fra tidligere USD 70-130 mio. Opjusteringen kan henf&#xf8;res til stigende markeder, og et forel&#xf8;bigt driftsresultat der er bedre end forventet. L&#xe6;s vores kommentar her, og tilmeld dig NORDEN&#x2019;s webcast i morgen kl. 10.00: <a href="https://www.inderes.dk/analyst-comments/norden-forelobige-tal-for-q3-2025-og-opjustering-af-2025-forventningerne" target="_blank" rel="noopener">https://www.inderes.dk/analyst-comments/norden-forelobige-tal-for-q3-2025-og-opjustering-af-2025-forventningerne</a>
Curasight meddelte her til morgen, at alle ni kliniske centre i Tyskland, Sverige og Danmark nu rekrutterer patienter til del 2 af selskabets fase 2-studie med uTRACE&#xae; i prostatakr&#xe6;ft, som gennemf&#xf8;res i samarbejde med Curium Inc. Rekrutteringen forventes afsluttet i f&#xf8;rste halv&#xe5;r 2026 og markerer solid operationel fremgang. Studiet har til form&#xe5;l at validere uTRACE&#xae; som et ikke-invasivt diagnostisk v&#xe6;rkt&#xf8;j til forbedret risikovurdering af prostatakr&#xe6;ftpatienter, hvor Curasight if&#xf8;lge aftalen med Curium er berettiget til op til USD 70 mio. i milep&#xe6;lsbetalinger samt tocifrede royaltyindt&#xe6;gter ved kommercialisering. Parallelt forventes et fase 1-studie med uTREAT&#xae; i hjernekr&#xe6;ft at blive igangsat senere i dette kvartal.
Wirteks CRO Niels Erik W&#xf8;hlk er blevet en del af SMV-r&#xe5;det i Energy Cluster Denmark, der skal styrke samarbejdet mellem teknologivirksomheder og den bredere energisektor. Initiativet underst&#xf8;tter Wirteks stigende fokus p&#xe5; energisektoren, hvor selskabets Energy-forretningsenhed voksede 84% &#xe5;r-til-&#xe5;r i 2024. Gennem klyngen &#xf8;nsker Wirtek at bidrage med ekspertise inden for IoT, software og indlejrede systemer for at fremme den digitale og gr&#xf8;nne omstilling.
Disclaimer: HC Andersen Capital modtager betaling fra de n&#xe6;vnte selskaber for en digital IR abonnementsaftale. /Jesper Thomsen d. 29/10-2025 kl. 8:58.

Dagens aktienyheder 29/10-2025: DS NORDEN, Curasight og Wirtek A/S

Stay up to date